What is HC Wainwright's Estimate for TARS Q2 Earnings?

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Tarsus Pharmaceuticals to loss of $0.12 per share, up from a prior estimate of $0.13 loss. The firm kept a Buy rating and $88 price target on the stock.
• Tarsus beat Q1 expectations, reporting EPS of -$0.16 versus the expected -$0.40, while revenue came in at $162.05 million, above estimates of $149.60 million.
• The company said XDEMVY net product sales topped $145 million in Q1, up more than 85% year over year, and it reaffirmed its 2026 sales guidance of $670 million to $700 million.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Research analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for Tarsus Pharmaceuticals in a research report issued to clients and investors on Thursday, May 7th. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.12) per share for the quarter, up from their prior forecast of ($0.13). HC Wainwright currently has a "Buy" rating and a $88.00 target price on the stock. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($0.70) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals' Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.49) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.24. The business had revenue of $162.05 million during the quarter, compared to analyst estimates of $149.60 million. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.

A number of other equities research analysts have also commented on TARS. The Goldman Sachs Group reissued a "neutral" rating and issued a $68.00 price target on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Wall Street Zen lowered Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, April 18th. Oppenheimer initiated coverage on Tarsus Pharmaceuticals in a research report on Friday, April 24th. They issued an "outperform" rating and a $98.00 price target for the company. Guggenheim increased their price target on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $90.67.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS opened at $61.21 on Monday. The firm has a market capitalization of $2.63 billion, a P/E ratio of -53.69 and a beta of 0.52. The business has a fifty day simple moving average of $68.72 and a 200 day simple moving average of $71.87. Tarsus Pharmaceuticals has a 12 month low of $38.51 and a 12 month high of $85.25. The company has a current ratio of 3.74, a quick ratio of 3.71 and a debt-to-equity ratio of 0.21.

Insider Activity

In other news, insider Jeffrey S. Farrow sold 2,186 shares of the firm's stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $146,462.00. Following the completion of the sale, the insider directly owned 43,316 shares of the company's stock, valued at $2,902,172. This trade represents a 4.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Elizabeth Yeu Lin sold 390 shares of the firm's stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $26,130.00. Following the sale, the insider directly owned 23,308 shares of the company's stock, valued at approximately $1,561,636. This represents a 1.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 79,391 shares of company stock worth $5,432,035. 9.64% of the stock is owned by insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Large investors have recently made changes to their positions in the business. Parallel Advisors LLC increased its position in shares of Tarsus Pharmaceuticals by 139.2% during the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company's stock valued at $35,000 after purchasing an additional 291 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Tarsus Pharmaceuticals by 367.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company's stock worth $50,000 after acquiring an additional 558 shares during the period. Comerica Bank grew its stake in shares of Tarsus Pharmaceuticals by 470.0% during the 4th quarter. Comerica Bank now owns 855 shares of the company's stock worth $70,000 after acquiring an additional 705 shares during the period. Truvestments Capital LLC grew its stake in shares of Tarsus Pharmaceuticals by 106.1% during the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company's stock worth $74,000 after acquiring an additional 468 shares during the period. Finally, Rockefeller Capital Management L.P. grew its stake in shares of Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company's stock worth $105,000 after acquiring an additional 172 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals News Roundup

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Tarsus reported Q1 EPS of -$0.16, beating expectations for a -$0.40 loss, and revenue of $162.05 million, above the $149.60 million consensus. Article Title
• Positive Sentiment: The company said Q1 XDEMVY net product sales topped $145 million, up more than 85% year over year, and reaffirmed 2026 guidance of $670 million to $700 million in XDEMVY sales. Article Title
• Neutral Sentiment: Management also highlighted broader business momentum, including stronger prescribing trends and the start of a Phase 2 Lyme disease prevention trial for TP-05. Article Title
• Neutral Sentiment: LifeSci Capital and HC Wainwright mostly kept bullish ratings on Tarsus, but several firms slightly lowered near-term EPS estimates after the report, which could temper enthusiasm. Article Title
• Negative Sentiment: Lifescis Capital cut Q1, Q2, Q3 and FY2026 EPS estimates, and HC Wainwright trimmed FY2027-FY2029 estimates slightly, reflecting continued losses in the near term despite long-term optimism. Article Title

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.